Full Text:   <125>

Summary:  <50>

CLC number: R184

On-line Access: 2020-08-04

Received: 2020-04-21

Revision Accepted: 2020-05-15

Crosschecked: 2020-07-20

Cited: 0

Clicked: 342

Citations:  Bibtex RefMan EndNote GB/T7714

 ORCID:

Yi-Da Yang

https://orcid.org/0000-0001-6261-0953

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2020 Vol.21 No.8 P.628-636

http://doi.org/10.1631/jzus.B2000211


Interferon-α2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients: a preliminary matched case-control study


Author(s):  Shao-Rui Hao, Ren Yan, Shan-Yan Zhang, Jiang-Shan Lian, Huan Cai, Xiao-Li Zhang, Lin Zheng, Hong-Yu Jia, Jian-Hua Hu, Guo-Dong Yu, Jue-Qing Gu, Chan-Yuan Ye, Ci-Liang Jin, Ying-Feng Lu, Jiao-Jiao Xin, Ji-Fang Sheng, Yi-Da Yang

Affiliation(s):  State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Department of Infectious Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China

Corresponding email(s):   yidayang65@zju.edu.cn

Key Words:  Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Propensity score match, Interferon (IFN)


Shao-Rui Hao, Ren Yan, Shan-Yan Zhang, Jiang-Shan Lian, Huan Cai, Xiao-Li Zhang, Lin Zheng, Hong-Yu Jia, Jian-Hua Hu, Guo-Dong Yu, Jue-Qing Gu, Chan-Yuan Ye, Ci-Liang Jin, Ying-Feng Lu, Jiao-Jiao Xin, Ji-Fang Sheng, Yi-Da Yang. Interferon-α2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients: a preliminary matched case-control study[J]. Journal of Zhejiang University Science B, 2020, 21(8): 628-636.

@article{title="Interferon-α2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients: a preliminary matched case-control study",
author="Shao-Rui Hao, Ren Yan, Shan-Yan Zhang, Jiang-Shan Lian, Huan Cai, Xiao-Li Zhang, Lin Zheng, Hong-Yu Jia, Jian-Hua Hu, Guo-Dong Yu, Jue-Qing Gu, Chan-Yuan Ye, Ci-Liang Jin, Ying-Feng Lu, Jiao-Jiao Xin, Ji-Fang Sheng, Yi-Da Yang",
journal="Journal of Zhejiang University Science B",
volume="21",
number="8",
pages="628-636",
year="2020",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2000211"
}

%0 Journal Article
%T Interferon-α2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients: a preliminary matched case-control study
%A Shao-Rui Hao
%A Ren Yan
%A Shan-Yan Zhang
%A Jiang-Shan Lian
%A Huan Cai
%A Xiao-Li Zhang
%A Lin Zheng
%A Hong-Yu Jia
%A Jian-Hua Hu
%A Guo-Dong Yu
%A Jue-Qing Gu
%A Chan-Yuan Ye
%A Ci-Liang Jin
%A Ying-Feng Lu
%A Jiao-Jiao Xin
%A Ji-Fang Sheng
%A Yi-Da Yang
%J Journal of Zhejiang University SCIENCE B
%V 21
%N 8
%P 628-636
%@ 1673-1581
%D 2020
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2000211

TY - JOUR
T1 - Interferon-α2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients: a preliminary matched case-control study
A1 - Shao-Rui Hao
A1 - Ren Yan
A1 - Shan-Yan Zhang
A1 - Jiang-Shan Lian
A1 - Huan Cai
A1 - Xiao-Li Zhang
A1 - Lin Zheng
A1 - Hong-Yu Jia
A1 - Jian-Hua Hu
A1 - Guo-Dong Yu
A1 - Jue-Qing Gu
A1 - Chan-Yuan Ye
A1 - Ci-Liang Jin
A1 - Ying-Feng Lu
A1 - Jiao-Jiao Xin
A1 - Ji-Fang Sheng
A1 - Yi-Da Yang
J0 - Journal of Zhejiang University Science B
VL - 21
IS - 8
SP - 628
EP - 636
%@ 1673-1581
Y1 - 2020
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2000211


Abstract: 
Background: Currently, there are no drugs that have been proven to be effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Because of its broad antiviral activity, interferon (IFN) should be evaluated as a potential therapeutic agent for treatment of coronavirus disease 2019 (COVID-19), especially while COVID-19-specific therapies are still under development. Methods: Confirmed COVID-19 patients hospitalized in the First Affiliated Hospital, School of Medicine, Zhejiang University in Hangzhou, China, from January 19 to February 19, 2020 were enrolled in a retrospective study. The patients were separated into an IFN group and a control group according to whether they received initial IFN-α2b inhalation treatment after admission. Propensity-score matching was used to balance the confounding factors. Results: A total of 104 confirmed COVID-19 patients, 68 in the IFN group and 36 in the control group, were enrolled. Less hypertension (27.9% vs. 55.6%, P=0.006), dyspnea (8.8% vs. 25.0%, P=0.025), or diarrhea (4.4% vs. 19.4%, P=0.030) was observed in the IFN group. Lower levels of albumin and C-reactive protein and higher level of sodium were observed in the IFN group. Glucocorticoid dosage was lower in the IFN group (median, 40 vs. 80 mg/d, P=0.025). Compared to the control group, fewer patients in the IFN group were ventilated (13.2% vs. 33.3%, P=0.015) and admitted to intensive care unit (ICU) (16.2% vs. 44.4%, P=0.002). There were also fewer critical patients in the IFN group (7.4% vs. 25.0%, P=0.017) upon admission. Although complications during admission process were comparable between groups, the discharge rate (85.3% vs. 66.7%, P=0.027) was higher and the hospitalization time (16 vs. 21 d, P=0.015) was shorter in the IFN group. When other confounding factors were not considered, virus shedding time (10 vs. 13 d, P=0.014) was also shorter in the IFN group. However, when the influence of other factors was eliminated using propensity score matching, virus shedding time was not significantly shorter than that of the control group (12 vs. 15 d, P=0.206). Conclusions: IFN-α2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients.

干扰素-α2b喷雾吸入未缩短住院患者的SARS-CoV-2的脱落时间:一项初步的配对病例对照研究

目的:分析干扰素-α2b(IFN-α2b)喷雾吸入治疗对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)在呼吸道病毒脱落时间的影响.
创新点:IFN在2019冠状病毒病(COVID-19)中的治疗价值尚未得到验证.
方法:我们进行了一项回顾性研究,纳入2020年1月19日至2月19日在中国杭州浙江大学医学院附属第一医院住院的104例确诊的COVID-19患者.根据入院时是否接受了初始IFN-α2b喷雾吸入治疗,将患者分为IFN组和对照组.采用倾向性得分匹配方法平衡混杂因素后,比较两组间住院时间和病毒脱落时间的差异.
结论:IFN-α2b喷雾吸入不能缩短COVID-19住院患者的住院时间和SARS-CoV-2的病毒脱毒时间.

关键词:2019冠状病毒病(COVID-19);严重急性呼吸综合征冠状病毒2(SARS-CoV-2);倾向性评分匹配;干扰素

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]Alhazzani W, Møller MH, Arabi YM, et al., 2020. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med, 46(5):854-887.

[2]Al-Tawfiq JA, Momattin H, Dib J, et al., 2014. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis, 20:42-46.

[3]Arabi YM, Shalhoub S, Mandourah Y, et al., 2020. Ribavirin and interferon therapy for critically ill patients with Middle East respiratory syndrome: a multicenter observational study. Clin Infect Dis, 70(9):1837-1844.

[4]Cao B, Wang YM, Wen DN, et al., 2020. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med, 382(19):1787-1799.

[5]Chan JFW, Yao YF, Yeung ML, et al., 2015. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis, 212(12):1904-1913.

[6]Channappanavar R, Fehr AR, Vijay R, et al., 2016. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe, 19(2):181-193.

[7]Cinatl J, Morgenstern B, Bauer G, et al., 2003. Treatment of SARS with human interferons. Lancet, 362(9380):293-294.

[8]Cinatl J Jr, Michaelis M, Scholz M, et al., 2004. Role of interferons in the treatment of severe acute respiratory syndrome. Expert Opin Biol Ther, 4(6):827-836.

[9]Danesh A, Cameron CM, León AJ, et al., 2011. Early gene expression events in ferrets in response to SARS coronavirus infection versus direct interferon-alpha2b stimulation. Virology, 409(1):102-112.

[10]Dusheiko G, 1997. Side effects of α interferon in chronic hepatitis C. Hepatology, 26(S3):112s-121s.

[11]Falzarano D, de Wit E, Martellaro C, et al., 2013a. Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci Rep, 3:1686.

[12]Falzarano D, de Wit E, Rasmussen AL, et al., 2013b. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med, 19(10):1313-1317.

[13]Ge ZY, Yang LM, Xia JJ, et al., 2020. Possible aerosol transmission of COVID-19 and special precautions in dentistry. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 21(5):361-368.

[14]Haagmans BL, Kuiken T, Martina BE, et al., 2004. Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med, 10(3):290-293.

[15]Kellum JA, Lameire N, Aspelin P, et al., 2012. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl, 2(1):1-138.

[16]Li GD, de Clercq E, 2020. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov, 19(3):149-150.

[17]Li HO, Zhou YJ, Zhang M, et al., 2020. Updated approaches against SARS-CoV-2. Antimicrob Agents Chemother, 64(6):e00483-20.

[18]Lu CW, Liu XF, Jia ZF, 2020. 2019-nCoV transmission through the ocular surface must not be ignored. Lancet, 395(10224):e39.

[19]Mantlo E, Bukreyeva N, Maruyama J, et al., 2020. Potent antiviral activities of type I interferons to SARS-CoV-2 infection. bioRxiv, preprint.

[20]National Health Commission of the People’s Republic of China, 2020. Chinese management guideline for COVID-19 (Version 7.0). http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml [Accessed on Mar. 4, 2020] (in Chinese).

[21]Omrani AS, Saad MM, Baig K, et al., 2014. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis, 14(11):1090-1095.

[22]Ren WB, Xia XJ, Huang J, et al., 2019. Interferon-γ regulates cell malignant growth via the c-Abl/HDAC2 signaling pathway in mammary epithelial cells. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 20(1):39-48.

[23]Shi Y, Wang G, Cai XP, et al., 2020. An overview of COVID-19. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 21(5):343-360.

[24]Spiegel M, Pichlmair A, Martínez-Sobrido L, et al., 2005. Inhibition of beta interferon induction by severe acute respiratory syndrome coronavirus suggests a two-step model for activation of interferon regulatory factor 3. J Virol, 79(4):2079-2086.

[25]Thiel V, Weber F, 2008. Interferon and cytokine responses to SARS-coronavirus infection. Cytokine Growth Factor Rev, 19(2):121-132.

[26]van Doremalen N, Bushmaker T, Morris DH, et al., 2020. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med, 382(16):1564-1567.

[27]World Health Organization, 2020. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance. https:// apps.who.int/iris/handle/10665/330854 [Accessed on Feb. 20, 2020].

[28]Wu ZY, McGoogan JM, 2020. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA, 323(13):1239-1242.

[29]Zhu N, Zhang DY, Wang WL, et al., 2020. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med, 382(8):727-733.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - Journal of Zhejiang University-SCIENCE